Ovid Therapeutics Inc. (OVID)

The long-term outlook is severely compromised by a brutal eight-year trajectory where the stock has lost over 95% of its value, driven by five consecutive years of negative annual returns ending with a sharp drop last year. While the company recently appointed new leadership to stabilize operations, the fundamental reality remains stark: negative free cash flow, negative operating margins, and a lack of profitability suggest the business is currently burning capital without generating returns. The valuation metrics reflect this distress, with a negative forward P/E and a price-to-book ratio that implies significant impairment relative to assets. On the short end, the picture is mixed; while the stock has rallied roughly 70% from its lows, the statistical forecasting model offers almost no directional guidance, and the heavy put writing suggests traders remain wary of further downside. With no dividend to provide income and a balance sheet showing significant cash burn, this remains a high-risk speculative vehicle rather than a viable investment.